Abstracts tagged "Janus kinase (JAK) and psoriatic arthritis"

Abstract Number: 1821 • 2018 ACR/ARHP Annual Meeting
Filgotinib, an Oral, Selective Janus Kinase 1 Inhibitor, Is Effective in Psoriatic Arthritis Patients with an Inadequate Response to Conventional Disease-Modifying Anti-Rheumatic Drugs: Results from a Randomized, Placebo-Controlled, Phase 2 Study
Philip J. Mease¹, Dafna D Gladman², Filip van Den Bosch³, Anna Rychlewska-Hanczewska⁴, Anna Dudek⁵, Chantal Tasset⁶, Luc Meuleners⁶, Pille Harrison⁷, Robin Besuyen⁶, Rebecca Kunder⁸, Neelufar Mozaffarian⁸, Laura C. Coates⁹ and Philip Helliwell¹⁰, ¹Swedish Medical Centre and University of Washington, United States of America, Seattle, WA, ²Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, University of Ghent, Ghent, Belgium, Ghent, Belgium, ⁴ai centrum medyczne sp.z o.o.sp.k., Poznan, Poland, Poznan, Poland, ⁵Centrum Medyczne AMED, Warszawa, Poland, Warszawa, Poland, ⁶Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁷Galapagos NV, Mechelen, Belgium, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ¹⁰Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK, Leeds, United Kingdom
Background/Purpose: Filgotinib (FIL) is an orally administered, selective Janus Kinase 1 (JAK1) inhibitor in development for inflammatory diseases. The efficacy and safety of FIL was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].